Clinical Outcome Measure
The predefined, quantified endpoint by which a trial judges whether the device helped — the quantity the study is actually powered to show. BCI trials mix performance metrics (information transfer rate, words or characters per minute, target-acquisition time, decoding accuracy) with function-and-life measures (patient-reported quality of life, communication ability, independence in daily digital tasks) and safety endpoints (adverse-event rates, signal longevity). Endpoints are designated primary versus secondary, and the primary endpoint together with its success threshold should be prespecified before the data are seen.
Performance metrics are seductive because they are objective and improve quickly, but they are surrogate outcomes: a high bits-per-minute figure does not by itself establish meaningful benefit to the person. Regulators and payers increasingly ask for validated, patient-centered outcomes and durability rather than peak laboratory performance, and the current lack of standardized, cross-study BCI outcome measures makes trials hard to compare.
A handwriting BCI reporting 90 characters per minute at 94 percent accuracy is impressive, but characters per minute is a surrogate. The patient-centered questions — can the user compose messages independently at home, does it hold up for months, does it improve their day — need separate, prespecified quality-of-life and durability endpoints to answer.
A high performance number is a surrogate; meaningful benefit needs its own validated endpoint.